Skip to main content

Table 1 Comparison of clinicopathological features according to HER-2 overexpression/amplification

From: Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial

Clinicopathological features

HER-2 overexpression/amplification

 

HER-2/neupositive (n = 27)

HER-2/neunegative (n = 200)

P

Age

  

0.151

  <65 years

18

96

  ≥65 years

9

104

Sex

  

0.765

  male

18

139

  female

9

61

Lauren

  

0.001

  intestinal

26

118

  diffuse

0

49

  mixed

1

33

WHO classification

  

0.001

  W/D

9

24

  M/D

16

97

  P/D

2

79

Tumor size

  

0.002

  ≥5 cm

18

72

  <5 cm

9

128

Tumor location

  

0.258

  cardia

21

128

  corpus

5

45

  antrum

1

27

Invasion depth

  

0.322

  T1

1

19

  T2

4

32

  T3

22

149

Lymph node

  

0.022

  present

20

118

  absent

7

82

TNM stage

  

0.320

  I

3

43

  II

6

52

  III

18

105

Vessel invasion

  

0.241

  present

4

16

  absent

23

184

Borrmann

  

0.133

  I

4

26

  II

17

102

  III

6

64

  IV

0

8

  1. M/D: moderately differentiated; P/D: poorly differentiated; W/D: well differentiated
  2. WHO: World Health Organization.